Headquartered in San Carlos, CA Fiscal year ends December NASDAQ: PCVX vaxcyte.com
Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect against bacterial diseases. The company's lead candidate, VAX-31, is a 31-valent pneumococcal conjugate vaccine (PCV) — the broadest-spectrum PCV candidate in clinical development — being evaluated in Phase 3 trials for adults and a Phase 2 study for infants for the prevention of invasive pneumococcal disease. Vaxcyte also develops VAX-24, a 24-valent PCV for infants, and VAX-XL, a next-generation preclinical PCV candidate designed for even broader coverage. Beyond pneumococcal disease, the company is advancing VAX-A1, a prophylactic vaccine candidate targeting Group A Streptococcus (now in Phase 1), and VAX-GI, a vaccine candidate for Shigella prevention. Vaxcyte's proprietary XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, enables the production of complex proteins and antigens outside of conventional cell-based manufacturing systems. The company generates no product revenue and funds operations through its cash reserves and capital raises. It trades on the Nasdaq under the ticker PCVX. Updated
Retail investors who spotted Seth Klarman buying Vaxcyte in May were already two months behind a trade Baupost had quietly begun unwinding. Understanding exactly what got lost in that gap changes how…
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
2020 will forever be remembered as the year the coronavirus pandemic broke out. But in the year of the lockdowns, there were also 480 initial public offerings on the U.S. stock market…
Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect against bacterial diseases.
24/7 Wall St.'s 12-month price target for PCVX is $134.89, rated Buy. The Wall Street consensus target is $117.30. PCVX price prediction →
